Dosing of 57 enrolled patients was completed in the Phase III trial of the RS5614 combination therapy. Data analysis and preparation of the clinical study report will follow. Direct impact on fiscal 2027 performance is currently unknown.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4889","jir_company_name":"Renascience Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4889-20260929-01.pdf","jir_short_summary":"Dosing of 57 enrolled patients was completed in the Phase III trial of the RS5614 combination therapy. Data analysis and preparation of the clinical study report will follow. Direct impact on fiscal 2027 performance is currently unknown.","jir_summary":"### Completion of the Clinical Trial and Next Steps for Evaluation\nDosing for all 57 enrolled patients in the investigator-initiated Phase III trial of RS5614 combination therapy for chronic myeloid leukemia (CML) was completed on September 29, 2026. This investigational therapy, administered in combination with TKIs, aims to achieve deep molecular response (DMR). The results will be summarized in a clinical study report and undergo data analysis and evaluation. With support from AMED, the project will continue to evaluate a treatment strategy aiming for treatment-free remission (TFR) after maintaining DMR for more than two years.\n\n### Future Schedule and Impact\nThis trial is a confirmatory study intended to support regulatory approval; if efficacy is demonstrated, it could provide a new treatment option for CML patients. At this time, the direct impact on fiscal 2027 results is unknown, and future valuation and development progress may be reflected in corporate value depending on trial outcomes.","jir_financial_highlights":"Impact on fiscal 2027 results: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Renascience, #ClinicalTrial, #GeneralIR","jir_key_figures":"57 people: Number of enrolled patients \/ dosing completed\n2026-09-29: Dosing completion date\nImpact on fiscal 2027 results: Unknown","jir_meta_title":"Renascience Inc. Announces Completion of Patient Dosing in RS5614 Phase III Trial\uff5c2026\/09\/29","jir_meta_description":"Renascience Inc. reports completion of dosing for 57 patients in the Phase III combination trial of RS5614. Data analysis and clinical study report preparation are planned. Impact on fiscal 2027 results is undetermined.","jir_og_title":"Renascience Inc. Announces Completion of Dosing for 57 Patients in RS5614 Phase III Trial","jir_og_description":"Renascience Inc. has announced dosing completion for 57 patients in the Phase III CML trial. Data analysis and preparation of the clinical study report will follow. The impact on fiscal 2027 results is currently unknown.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57877,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-124316","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n